• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·GENB
Share

Generate Biomedicines, Inc. Stocks

$ 12.97Last Updated 01.06.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 1.66B

$ 12.97
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

01.03.2026 22:00

$110 billion OpenAI, SpaceX and crypto-payments operator RedotPay: What's important about the IPO by March 1

27.02.2026 15:00

IPO Generate Biomedicines: shares of AI drug development platform become available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of GENB is 27 and suggests 108% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.06.2026 00:20

Investors began to see HPE stock as a bet on AI: report lifted the securities by 37%

02.06.2026 23:13

Victoria's Secret stock soared 45%. The sexy bet worked

02.06.2026 22:10

Musk recalled a 1,000-fold rise in Tesla's stock price. Can SpaceX rise in price the same way?

02.06.2026 21:48

Gold has regained its status as the largest reserve asset of central banks - ECB

02.06.2026 20:24

Nvidia CEO predicts $1 trillion capitalization for Marvell. Shares soar 25%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026